Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): BOOK

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

and status : DETACHER

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: To demonstrate to the audience a combined facelift with fat grafting using a new injectable tissue replacement technique that modifies the fat graft into 3 parcel sizes to anatomically replace deep and superficial compartment fat loss, areas of bone loss and areas of epithelial and dermal thinning.

Introduction: Background: Patients with facial aging present with three to four major phenotypic findings that concern them enough to seek out surgical consultation. Sun damage, volume loss and laxity along with creasing secondary to facial expression are treated with a continuum of care approach, selecting the most appropriate treatment for the severity of the physical finding.

Materials / method: Materials and Methods: In replacing losses in soft tissue and bone in the aging face, we are applied an anatomic technique (ITR2) of modifying the fat graft into three types: a millifat (parcel size 2 mm); a microfat (1 mm) and a nanofat (>800 microns). Deep fat compartment, lip, columellar and bone losses are replaced with millifat which is a more structural graft, whereas, superficial fat compartment losses are replaced with microfat, a smaller graft used as a single layer. Nanofat is injected for regeneration of intradermal and epithelial tissues.

Results: All areas of soft tissue and bone loss are replaced with milli and microfat prior to the facelift, whereas, nanofat is delivered following the facelift procedure. Complications have occurred in 3 patients who required a small amount of fat to be removed from their lower eyelids using a blepharoplasty approach. None of these patients had any residual long term sequelae. There was one case of flap necrosis, but this did not appear related to the fat grafting aspect of the surgery and the patient was a non-smoker. No hematomas occurred.

Conclusion: In a small study of 12 hemi-midfacial regions with 3D photometry, a reduction in the rate of tissue decay was seen. ITR2 provides a precise anatomic replacement of tissues lost in the aging process. Combining the appropriate facelift technique based on the severity and type of physical findings addresses laxity, while facial volume is restored with anatomically precise fat grafts placed in the regions of loss.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): Tulip- royalties on fat press (pending); Millenium Medical (royalites on kits, stock options in lieu of consulting)

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): Tulip- royalties on fat press (pending); Millenium Medical (royalites on kits, stock options in lieu of consulting)

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability